Roche and Geli work together to customize innovative hepatitis C drug danoprevir for Chinese patients

At present, there are about 10 million patients with chronic hepatitis C in China, most of them are 1b type Patients with this genotype have been shown to have a high response rate to danoprevier Therefore, Roche and Geli decided to jointly develop the new drug, which will help alleviate the serious public health problem of hepatitis C and provide a new and effective treatment scheme for the vast number of hepatitis C patients in China According to the cooperation agreement, Geli will be responsible for the development, registration and production of danoprevir in mainland China, Hong Kong, Macao and Taiwan Roche will pay Geli the mileage fund for drug development and commercialization according to the phased results The two sides will cooperate in clinical development and commercial operation The sales commission is also involved in the cooperation agreement Speaking of the cooperation, Mr Lu Ke, President of Roche pharmaceutical Asia Pacific region, said: "the starting point of Roche's strategy is to bring innovative and differentiated drugs to patients Roche decided to develop danoprevir, an innovative drug, because it has a bright future in the treatment of hepatitis C 1B gene patients, and the choice to work with Geli is another embodiment of Roche's strategy into action " Dr Wu JINZI, President and CEO of Geli Biotechnology (Hangzhou) Co., Ltd., said: "currently, there is no hepatitis C treatment drug (DAAS) that directly affects the virus in the Chinese market." Roche is a global leader in the research and development of innovative hepatitis C drugs, and Geli is very honored to cooperate with Roche to customize this innovative hepatitis C drug for Chinese patients, and finally put it to the market Up to now, danoprevir's clinical trial data are very encouraging, and we look forward to this innovative drug benefiting more hepatitis C patients as soon as possible " Danoprevir is a protease inhibitor of Roche, which has significant therapeutic effect on type 1 and type 4 hepatitis C patients Protease inhibitors have become the core components of effective hepatitis C drugs in the future Geli Biotechnology (Hangzhou) Co., Ltd is a new biotech company dedicated to the discovery, development and commercialization of important new therapies for cancer and infectious diseases Geli focuses on the clinical development and production of innovative drugs for the developing Chinese pharmaceutical market Geli is composed of entrepreneurial management and senior scientific research team, with the experience of successfully discovering and developing drugs for large multinational pharmaceutical and emerging biotechnology companies in the United States and Europe For more information, please visit http:// and http:// Roche, headquartered in Basel, Switzerland, is the world's leading R & D-based, innovation driven health care company in the field of pharmaceuticals and diagnostics As the world's largest biotechnology company, Roche has effective differentiated drugs in the fields of anti-tumor, anti-virus, inflammation, metabolism and central nervous system At the same time, Roche is also a market leader in in vitro diagnosis and tissue-based tumor diagnosis, as well as a pioneer in the field of diabetes management Roche's "individualized medical treatment" program aims to provide innovative drugs and diagnostic tools, so as to effectively improve human health standards, quality of life and the survival of patients In 2012, Roche had more than 82000 employees worldwide, invested more than 8 billion Swiss francs in R & D projects and sold 45.5 billion Swiss francs Genentech in the United States is one of the group members wholly owned by Roche, and Roche is also the holding Party of Chugai.